Cargando…
Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts
CD22 is a cell-surface adhesion molecule on most B-cell NHL, so it is a promising target for immunotherapy. HB22.7 is an anti-CD22 mAb that binds the two NH(2)-terminal immunoglobulin domains and specifically blocks the interaction of CD22 with its ligand. CD22-blocking mAbs induce apoptosis in neop...
Autores principales: | O’Donnell, Robert T., Ma, Yunpeng, McKnight, Hayes C., Pearson, David, Tuscano, Joseph M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749165/ https://www.ncbi.nlm.nih.gov/pubmed/19437017 http://dx.doi.org/10.1007/s00262-009-0713-8 |
Ejemplares similares
-
The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner
por: Martin, Shiloh M, et al.
Publicado: (2011) -
Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin’s lymphoma
por: Kato, Jason, et al.
Publicado: (2012) -
The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone
por: Tuscano, Joseph M., et al.
Publicado: (2011) -
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
por: O’Donnell, Robert T., et al.
Publicado: (2009) -
A Fermented Wheat Germ Extract Contains Protein Components Active against NSCLC Xenografts In Vivo
por: Levis, Daniel J., et al.
Publicado: (2023)